BofA raised the firm’s price target on Kymera Therapeutics (KYMR) to $72 from $54 and keeps a Buy rating on the shares. Given the sizable atopic dermatitis market and Dupixent’s dominant role as the current standard-of-care, the firm views Kymera’s upcoming Phase 1b BroADen data readout as “a key derisking event” and breaks out value for KT-621 in AD at $26 per share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
- Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis
- Kymera Therapeutics presents new preclinical data for KT-579
- Citi places ‘upside 90-day catalyst watch’ Kymera into data
- Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo